» Articles » PMID: 29879043

Risk Factors Associated with Overweight and Obesity in HIV-infected People: Aging, Behavioral Factors but Not CART in a Cross-sectional Study

Abstract

Identifying risk factors associated with overweight and obesity in HIV-infected patients.A cross-sectional study analyzing data from patients attending an HIV outpatient unit. Overweight was defined as body mass index (BMI) ≥25 kg/m; <30 kg/m, obesity was ≥30 kg/m. Patients' characteristics contemporary to BMI assessment were collected. Multivariate logistic regression identified risk factors associated with overweight/obesity.Eight hundred sixty-two patients, median age 51 years, 21.5 years of HIV infection follow-up, 585 (68%) male, 829 (96%) receiving combined antiretroviral therapy (cART) for median 16.7 years, 768 (91%) HIV load <40 copies/mL, 618 (73%) CD4 ≥500 cells/mm; 266 (31%) HCV serology, 110 (13%) had detectable HCV-RNA. Overweight affected 191 (22%) patients and obesity 46 (5%). Overweight and obesity were associated with age, HIV follow-up duration, and HIV transmission risk group. Overweight was also associated with gender and HCV status. In patients with substance use data, overweight was associated with alcohol and nonsmoking status. Obesity was associated with nonsmoking and ex-smoker status. Overweight/obesity were not found associated with cART or immune cell counts.In HIV-infected people, aging, alcohol consumption, nonsmoking, and ex-smoker status, the absence of HCV coinfection and to have cleared HCV infection are associated with overweight and/or obesity. Clinicians should be aware of these trends and consider introducing weight management programs as part of routine HIV care.

Citing Articles

Comorbidities and HIV-related factors associated with mental health symptoms and unhealthy substance use among older adults living with HIV in low- and middle-income countries: a cross-sectional study.

Ross J, Rupasinghe D, Chanyachukul T, Crabtree Ramirez B, Murenzi G, Kwobah E J Int AIDS Soc. 2025; 28(3):e26434.

PMID: 40045453 PMC: 11882396. DOI: 10.1002/jia2.26434.


Overweight and Obesity Among People Living With HIV on Dolutegravir- and Efavirenz-Based Therapies: A Comparative Cross-Sectional Study.

Jemal M, Adugna A, Getinet M, Baylie T, Waritu N AIDS Res Treat. 2024; 2024:5347620.

PMID: 39735593 PMC: 11671659. DOI: 10.1155/arat/5347620.


Obesity Defining Criteria, and Association with Cardiovascular Disease Risk Factors Among People Living with HIV in Jos, Nigeria.

Imoh L, Selowo T, Olaniru O, Abene E, Gimba Z, Davwar P Niger Med J. 2024; 65(4):490-502.

PMID: 39398407 PMC: 11470281. DOI: 10.60787/nmj-v65i3-478.


Protocol for the LIFEH project: a prospective observational study to explore lifestyle among people living with HIV experiencing weight gain, looking beyond antiretroviral therapy.

Zanini B, Salvi M, Marconi S, Tiecco G, Gilberti G, Castellano M BMJ Open. 2024; 14(9):e086866.

PMID: 39260867 PMC: 11409257. DOI: 10.1136/bmjopen-2024-086866.


12-week Dolutegravir treatment marginally reduces energy expenditure but does not increase body weight or alter vascular function in a murine model of Human Immunodeficiency Virus infection.

Kress T, Ajala P, Jordan C, Mintz J, MacArthur R, Kennard S Vascul Pharmacol. 2024; 155:107288.

PMID: 38428626 PMC: 11189738. DOI: 10.1016/j.vph.2024.107288.


References
1.
Wyles D, Ruane P, Sulkowski M, Dieterich D, Luetkemeyer A, Morgan T . Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015; 373(8):714-25. DOI: 10.1056/NEJMoa1503153. View

2.
Gomes A, Reyes E, Garduno L, Rojas R, Mir Mesejo G, Del Rosario E . Incidence of Diabetes Mellitus and Obesity and the Overlap of Comorbidities in HIV+ Hispanics Initiating Antiretroviral Therapy. PLoS One. 2016; 11(8):e0160797. PMC: 4979961. DOI: 10.1371/journal.pone.0160797. View

3.
Bray G . Complications of obesity. Ann Intern Med. 1985; 103(6 ( Pt 2)):1052-62. DOI: 10.7326/0003-4819-103-6-1052. View

4.
Tate T, Willig A, Willig J, Raper J, Moneyham L, Kempf M . HIV infection and obesity: where did all the wasting go?. Antivir Ther. 2012; 17(7):1281-9. PMC: 3779137. DOI: 10.3851/IMP2348. View

5.
Alter M . Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2005; 44(1 Suppl):S6-9. DOI: 10.1016/j.jhep.2005.11.004. View